State of New Jersey Common Pension Fund D Purchases New Position in Sarepta Therapeutics, Inc. $SRPT

State of New Jersey Common Pension Fund D purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,940 shares of the biotechnology company’s stock, valued at approximately $730,000.

Several other institutional investors and hedge funds have also bought and sold shares of SRPT. Yousif Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 1.9% during the 4th quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock worth $541,000 after acquiring an additional 481 shares during the period. Arizona State Retirement System boosted its position in shares of Sarepta Therapeutics by 2.8% during the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock valued at $504,000 after purchasing an additional 717 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its stake in Sarepta Therapeutics by 6.1% in the third quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 728 shares during the period. Thrivent Financial for Lutherans grew its stake in Sarepta Therapeutics by 3.3% in the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Sarepta Therapeutics by 1.8% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after purchasing an additional 758 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SRPT shares. Loop Capital set a $25.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Wedbush upped their price objective on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 26th. Finally, Wells Fargo & Company lowered their target price on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $27.71.

Insider Activity at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the sale, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by insiders.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $19.40 on Tuesday. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -20.21, a PEG ratio of 0.29 and a beta of 0.26. The firm’s 50-day moving average is $19.83 and its 200 day moving average is $20.25. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $44.14. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. The business had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. Sarepta Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the business earned ($3.42) EPS. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.89 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.